The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
Wake Forest University Health Sciences
UMC Utrecht
Boehringer Ingelheim
University of California, Irvine
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Baylor College of Medicine
University of Colorado, Denver
Alliance for Clinical Trials in Oncology
SystImmune Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Daiichi Sankyo
University of Nebraska
Zhejiang University
Kidney Cancer Research Bureau
Adela, Inc
Sichuan Baili Pharmaceutical Co., Ltd.
Var2 Pharmaceuticals
Elephas
VM Oncology, LLC
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
University of Colorado, Denver
British Columbia Cancer Agency
Washington University School of Medicine
Travera Inc
A2 Biotherapeutics Inc.
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
The Netherlands Cancer Institute
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Stanford University
Apollomics Inc.
University of California, Irvine
Cancer Research UK
Columbia University
Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, Nanjing Medical University
University Health Network, Toronto
Centre Hospitalier Universitaire de Besancon
Pack Health
University Health Network, Toronto
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Zhejiang Provincial People's Hospital